



Primary surgical management of anterior pelvic organ prolapse: a systematic review, network meta-analysis and cost-effectiveness analysis

E Slade,^a  C Daly,^b I Mavranzouli,^{a,c} S Dias,^{b,d}  R Kearney,^{e,f} E Hasler,^a P Carter,^{a,c}
C Mahoney,^g F Macbeth,^h V Delgado Nunes^a

^a National Guideline Alliance, Royal College of Obstetricians and Gynaecologists, London, UK ^b Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK ^c Research Department of Clinical, Educational and Health Psychology, University College London, London, UK ^d Centre for Reviews and Dissemination, University of York, York, UK ^e The Warrell Unit, St Mary's Hospital, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK ^f Faculty of Medical Human Sciences, University Institute of Human Development, University of Manchester, Manchester, UK ^g Manchester University Hospitals NHS Foundation Trust, Manchester, UK ^h Centre for Trials Research, Cardiff University, Cardiff, UK

Correspondence: E Slade, National Guideline Alliance, Royal College of Obstetricians and Gynaecologists, 27 Sussex Place, London NW1 4RG, UK. Email: eslade@rcog.org.uk

Accepted 9 September 2019. Published Online 16 October 2019.

Background Anterior compartment prolapse is the most common pelvic organ prolapse (POP) with a range of surgical treatment options available.

Objectives To compare the clinical effectiveness and cost-effectiveness of surgical treatments for the repair of anterior POP.

Methods We conducted a systematic review of randomised controlled trials comparing surgical treatments for women with POP. Network meta-analysis was possible for anterior POP, same-site recurrence outcome. A Markov model was used to compare the cost-utility of surgical treatments for the primary repair of anterior POP from a UK National Health Service perspective.

Main results We identified 27 eligible trials for the network meta-analysis involving eight surgical treatments tested on 3194 women. Synthetic mesh was the most effective in preventing recurrence at the same site. There was no evidence to suggest a difference between synthetic non-absorbable mesh, synthetic partially

absorbable mesh, and biological mesh. The cost-utility analysis, which incorporated effectiveness, complications and cost data, found non-mesh repair to have the highest probability of being cost-effective. The conclusions were robust to model inputs including effectiveness, costs and utility values.

Conclusions Anterior colporrhaphy augmented with mesh appeared to be cost-ineffective in women requiring primary repair of anterior POP. There is a need for further research on long-term effectiveness and the safety of mesh products to establish their relative cost-effectiveness with a greater certainty.

Keywords Anterior prolapse, cost-effectiveness, mesh, National Institute for Health and Care Excellence, network meta-analysis, outcome research, pelvic organ prolapse.

Tweetable abstract New study finds mesh cost-ineffective in women with anterior pelvic organ prolapse.

Please cite this paper as: Slade E, Daly C, Mavranzouli I, et al. Primary surgical management of anterior pelvic organ prolapse: a systematic review, network meta-analysis and cost-effectiveness analysis. BJOG 2019; <https://doi.org/10.1111/1471-0528.15959>.

Introduction

Anterior compartment prolapse is the most common pelvic organ prolapse (POP) with a lifetime risk of surgery estimated between 11 and 19%.¹ Anterior POP is defined as the descent of the anterior vaginal wall.² Treatments include conservative or surgical options, and depend on symptoms, POP degree and patient preferences.³

Anterior colporrhaphy (AC) is considered the standard surgical treatment but is associated with a significant rate of failure.⁴ Surgery with mesh augmentation was

introduced to improve outcomes but there are safety concerns about its use and no data on long-term outcomes.¹ Synthetic meshes may lead to chronic complications needing long-term management. To address these concerns, NHS England set up the Mesh Working Group and an independent review of transvaginal mesh implants was undertaken in Scotland.^{5,6} Mesh products have also been scrutinised by the European Commission (SCENIHR) and the US Food and Drug Administration.^{7,8}

The aim of this work was to evaluate which surgical procedures are the most clinically effective and cost-effective in

women undergoing repair of anterior POP. This analysis was used to inform a national guideline on the management of urinary incontinence and POP in women, released by the National Institute for Health and Care Excellence (NICE) in England.⁹

Methods

Methods of the systematic review and network meta-analysis

We carried out a systematic review to identify relevant randomised controlled trials (RCTs) using a predefined search strategy (see Supplementary material, Appendix S1). The final search date was June 2018. A 10% random sample of the literature search results was screened by a second reviewer against inclusion criteria specified in the review protocol.⁹

One reviewer extracted data from the eligible studies, including study characteristics, aspects of methodological quality, outcome data and risk of bias, which were checked by a second reviewer.¹⁰

Randomised controlled trials on surgical procedures in women with predominantly anterior, primary or secondary repair were included. The critical outcomes in the systematic review were health-related quality of life, adverse events and complications including recurrence of POP. The recurrence of anterior POP was the only dichotomous outcome that could be synthesised using network meta-analysis (NMA). Data were poorly reported for other outcomes and were insufficient to inform NMA.

Network meta-analysis combines direct and indirect evidence to estimate relative effects between all pairs of interventions in a network, even if some pairs of interventions have not been directly compared in head-to-head trials.^{11–14} Fixed and random effects NMA models (binomial likelihood and cloglog link) were fitted in a Bayesian framework, using WINBUGS 1.4.3.^{12,15} The goodness-of-fit of each model was assessed and the model with best fit was selected as the base-case NMA model (see Supplementary material, Appendix S2).

Relative effects between surgical procedures were expressed as posterior median hazard ratios (HR) with 95% credible intervals (CrI). Surgical procedures were also ranked based on their effectiveness, with a rank of 1 representing the best procedure. Median ranks and 95% CrI are presented for each surgical procedure.

The suitability of the consistency assumption was assessed by comparing the selected base-case NMA model to an 'inconsistency', or unrelated mean effects, model and by node-splitting.^{16–18} (see Supplementary material, Appendix S2).

Methods for the cost-effectiveness analysis

We developed a de novo Markov model to estimate the cost-effectiveness of effective surgical procedures over

15 years in adult women who required surgical repair for primary anterior POP using the data obtained from the NMA (see Supplementary material, Appendix S3). The model was run in yearly cycles and included the following health states: 'well' (i.e. successfully managed POP), 'failure/recurrence' and 'complications'. The model considered only one recurrence following the primary repair given that few women have more than two repairs.¹⁹

Clinical inputs

The baseline risk of anatomical recurrence was estimated by combining the probability of surgically managed recurrence derived from a long-term naturalistic study with the probability of anatomical recurrence adjusted for the surgically managed recurrence that was derived from the AC arm of the RCT with the longest available follow up among those included in the systematic review.^{19,20}

This approach was used because the identified naturalistic studies focused only on surgically managed recurrence and the effectiveness data estimated from the NMA were for anatomical recurrence. Identified long-term rates were used to estimate the annual probabilities of recurrence. Given the uncertainty about how the recurrence risk varies with time, a constant risk was modelled each year for the duration of the model.

We applied the HR from the NMA to the baseline risk for the reference surgical procedure (AC), to obtain absolute probabilities for all surgical treatments. Given that the follow-up times in RCTs included in the NMA were clustered around 1–3 years the estimated HR of mesh procedures (versus AC) were applied during the first 3 years only. After the 3 years, the risk of recurrence in mesh groups was modelled to be the same as for women receiving AC only.

The risk of surgically managed recurrence following a secondary repair was based on an observational cohort study.²¹ This study did not report the anatomical recurrence rate so this was taken from a UK-based RCT.²² The annual probabilities were estimated as described above for the primary repair.

The mortality rate from POP surgery is small (37 per 100 000 cases) and would only make a very small contribution to the health state utility loss because mortality is not expected to vary between surgical procedures and very few women choose to undergo further repairs following POP recurrence.²³ Therefore, mortality was not considered in the analysis.

Complications

Surgical complications other than those associated with the mesh itself were not deemed to vary much across arms and were excluded from the analysis. Surgical treatment with mesh is associated with various complications. Given the

uncertainty about the long-term incidence of complications, only those assumed to have the greatest impact on health-related quality of life and costs, including mesh extrusion and pain, were modelled.

Rates of mesh extrusion and pain were taken from cohort studies and were used to estimate the annual probabilities attached to the synthetic mesh repairs.^{24,25} As women continue to develop complications during long-term follow up, the estimated annual probabilities were applied at each year for the duration of the model.

It is not known what proportion of mesh complications, including mesh extrusion and pain, resolve over time. Based on the NICE Guideline Committee (GC) expert opinion, the model assumed that most complications will resolve by year two and a small proportion of mesh complications (10%) will persist for the duration of the model. The complication data were insufficient to differentiate between different synthetic mesh types (non-absorbable and partially absorbable).

The systematic review indicated that the risk of mesh extrusion was lower for biological mesh than for synthetic mesh.⁹ The risk ratio estimated from the systematic review was applied to the risk of mesh extrusion with synthetic mesh to estimate the annual risk of mesh extrusion associated with the biological mesh.⁹ However, given the lack of long-term clinical data on pain complications associated with the biological mesh, the same rate as for synthetic mesh was used in the analysis.

Cost data

We adopted a UK NHS perspective and considered costs of surgical procedures, mesh products, conservative management, repeat surgery and complication management.

The repeat surgery cost was modelled as the average of surgical mesh and non-mesh procedure costs, and also an apical procedure cost as recurrent anterior vaginal wall POP could be associated with apical descent.

The cost associated with conservative management was obtained from a UK-based RCT that included treatment with pelvic floor exercises, estrogens and pessaries.²⁶ It was assumed that only half of women experiencing recurrence would require treatment; symptoms in other women were not severe enough to require treatment for their POP.²⁷

The economic analysis also included complementary tests (blood tests, and urea and electrolytes) and consultations that would typically be carried out before and after surgery.

It was assumed that just over half of women with a mesh extrusion would require surgical revision, whereas for the rest treatment included topical estrogens and close surveillance.²⁴ Pain management included pharmacological treatments, vaginal estrogen, dilators, psychosexual counselling, physiotherapy, or mesh removal. Costs associated with persistent mesh complications were modelled to be equivalent to the initial management cost. Therefore, the initial cost

associated with a complication was apportioned over the time horizon of the model to approximate the annual cost associated with managing persistent mesh complications.

Unit costs were derived from national sources expressed in 2016/17 prices.^{28–31}

Utility values

In order to express outcomes in the form of quality-adjusted life-years (QALYs), the health states of the economic model needed to be linked to appropriate utility scores. Utility values were required for active POP, resolved POP, recurrent POP and complications. Utility estimates were derived from the published UK RCT that reported the EuroQol (EQ-5D-3L) utility scores, estimated using the UK Time Trade-Off Tariff.²⁶

Handling uncertainty

To account for the uncertainty around the input parameter point estimates, a probabilistic analysis was undertaken, in which input parameters were assigned probabilistic distributions.³² Subsequently, 10 000 iterations were performed, each drawing random values out of the specified distributions. Mean costs, QALYs and the Net Monetary Benefit (NMB) for each surgical treatment were calculated by averaging across 10 000 iterations. We conducted a full incremental analysis, reporting incremental cost-effectiveness ratios, interpreted as the additional expected cost per additional unit gain in utility for a surgical procedure compared with the previous non-dominated surgical procedure. We represented uncertainty in the optimal surgical procedure by estimating the probability of each surgical procedure being cost-effective at £20,000–£30 000 threshold values. A range of deterministic sensitivity analyses were undertaken.

The Supplementary material (Table S1) summarises all model inputs including clinical data inputs, cost data and utility estimates, and evidence sources; and provides details on the types of distributions assigned to each.

Results

Results of the systematic review and NMA

A total of 2378 studies were identified in the literature searches with 27 trials (3194 participants) contributing data to the NMA outcome of same-site recurrence (Figure 1).

Eight surgical procedures were included. One study was excluded from the NMA because treatments were not connected to the rest of the network.^{33,34} A further study was excluded because the definition of recurrence was unclear.³⁴ The resulting network of trials contributing data to the NMA is presented in Figure 2. The details of the included studies in the NMA and the final data file used are presented in the Supplementary material (Table S2 and S3, respectively).




Figure 1. Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) flowchart.

Approximately 30% of the included trials were assessed as being unclear or at high risk of selection bias, namely for allocation concealment and sequence generation. Not unexpectedly, the majority of trials (96%) were unclear or at high risk of performance bias for blinding, as blinding is more difficult to incorporate in trials of surgical procedures. Approximately 40% of the included trials were

unclear or at high risk of attrition bias, reporting bias and other biases.

Each NMA model (fixed or random effects) was run until convergence was satisfactory; results were then based on a further sample of iterations on three separate chains. The random effects model had more favourable fit to the data, and so all further analyses are based on that model




Figure 2. Network diagram of all studies included in the analysis of recurrence at the same site in women undergoing primary repair of anterior POP.

($\tau = 0.63$, 95% CrI 0.38–0.97). (see Supplementary material, Appendix S2).

Table 1 reports the posterior median HR and 95% CrI for each surgical procedure relative to AC for recurrence outcome. Paravaginal repair and synthetic non-absorbable mesh had the lowest HR (best) of recurrence when compared with AC (HR 0.25, 95% CrI 0.04–1.26). However, this procedure was tested on small numbers of women across studies and the result was characterised by considerable uncertainty, as indicated by wide 95% CrI.

There was evidence to suggest that AC with synthetic non-absorbable mesh (HR 0.38, 95% CrI 0.24–0.59), AC with synthetic partially absorbable mesh (HR 0.27, 95% CrI 0.11–0.62), and AC with biological mesh (HR 0.44, 95% CrI 0.26–0.73) were more effective when compared with AC alone. However, there was no difference between various mesh types.

The treatment with the best posterior median rank was AC with synthetic partially absorbable mesh (1st, 95% CrI 1st to 5th) followed by paravaginal repair with synthetic non-absorbable mesh (2nd, 95% CrI 1st to 7th), AC with synthetic non-absorbable mesh (3rd, 95% CrI 1st to 6th), AC with biological mesh (4th, 95% CrI 1st to 6th), AC with synthetic absorbable mesh, paravaginal repair with biological mesh (6th, 95% CrI 2nd to 8th), and AC only (7th, 95% CrI 5th to 8th).

No evidence of inconsistency between direct and indirect estimates was identified (see Supplementary material, Appendix S3).

Results of the cost-effectiveness analysis

Table 2 shows the expected total costs and QALYs for each surgical procedure. It also provides the results of the incremental analysis, the mean NMB of each procedure at the £20,000 per QALY threshold, the ranking of procedures by NMB, and also the probability of each surgical procedure being cost-effective at threshold values. Surgical procedures are ordered by increasing expected total cost. All treatments were dominated by AC, which was more effective in terms of increased QALYs and less expensive than all other surgical procedures (Table 2). AC with synthetic non-absorbable mesh had the highest expected cost and the lowest expected QALYs.

The expected NMB at a £20,000 threshold was highest for AC (£189,156), followed by AC with biological mesh (£187,869), AC with synthetic partially absorbable mesh (£186,337), and lowest for AC with synthetic non-absorbable mesh (£186,306). Also, AC has the highest probability of being cost-effective (Table 2). As the threshold increases, the probability of AC with biological mesh increases but this probability never exceeds 26%.

Sensitivity analyses

Results were robust to model inputs including effectiveness, costs and utilities. Under all scenarios examined, AC

remained the preferred surgical procedure. For example, in the base-case analysis, it was assumed that treatment effectiveness at 4 years onwards for mesh procedures will be the same as for AC. Assuming that treatment effectiveness is sustained for the duration of the model did not change the conclusions.

Most mesh extrusion cases happened in the first year with the risk decreasing over time.²⁴ This was derived from a small study and there were few data on the frequency of mesh complications occurring in the long-term; however, the NICE GC were aware of women who experienced mesh complications many years after mesh insertion. Nevertheless, the mesh was cost-ineffective even when we only used the available rates of mesh complications.

The results of all deterministic sensitivity analyses are presented in the Supplementary material (Table S4).

Discussion

Main findings

Overall, the results from the NMA indicate that the use of mesh is more successful than non-mesh surgical procedures in preventing anterior POP recurrence. The cost-effectiveness analysis attempted to bring together the information on clinical effectiveness, complications and costs, and suggested that, although mesh is more effective, it causes more complications and is cost-ineffective for women who require primary repair of anterior POP. It should be noted that the long-term safety of mesh is unclear and there is considerable uncertainty in this model input. Nevertheless, overall the conclusions were robust to changes in this and other model inputs.

Strengths and limitations

To our knowledge this is the first urogynaecological NMA to compare multiple competing treatments for POP in a cost–utility analysis. We conducted a detailed search, and took considerable effort to include all available RCT data. We synthesised the effectiveness data from multiple RCTs using NMA methodology, and, where possible, the long-term baseline risks and the incidence rates of complications were obtained from cohort studies with the longest available follow up.

Despite robust methodology, not all trials provided data on key outcomes and this is a limitation of the study. Although it could be argued that surgically managed recurrence is a more important efficacy measure, there were insufficient data to allow synthesis of trial data on this outcome using NMA methodology.

The length of follow up in the RCTs informing the NMA was clustered around 12–36 months and the cost-effectiveness analysis was confined to short-term effectiveness. Given the uncertainty surrounding the long-term

Table 1. Posterior median hazard ratios and 95% CrI for recurrence at the same site for every surgical procedure compared with each other in women with anterior POP

Paravaginal repair and biological mesh								0.84 (0.17, 4.22)
0.72 (0.05, 9.90)	Paravaginal defect repair (abdominal)	4.79 (0.32, 73.79)						
3.44 (0.66, 19.17)	Paravaginal repair and synthetic non-absorbable mesh	0.28 (0.03, 2.41)						0.25 (0.04, 1.37)
0.95 (0.12, 7.42)	AC and synthetic absorbable mesh	0.92 (0.14, 5.99)						0.88 (0.20, 3.96)
3.17 (0.56, 18.37)	AC and synthetic partially absorbable mesh*	0.61 (0.22, 1.63)					0.82 (0.17, 4.01)	0.25 (0.08, 0.72)
1.91 (0.39, 9.68)	AC and biological mesh*	0.70 (0.28, 1.71)					0.85 (0.27, 2.46)	0.48 (0.26, 0.89)
2.19 (0.46, 10.88)	AC and synthetic non-absorbable mesh*	1.15 (0.63, 2.13)					AC and synthetic non-absorbable mesh*	0.36 (0.20, 0.60)
0.84 (0.18, 3.82)		0.89 (0.22, 3.52)					0.44 (0.26, 0.73)	0.38 (0.24, 0.59) AC

Lower diagonal: Posterior median HR and 95% CrI from NMA. HR <1 favour the column defining treatment, HR >1 favour the row defining treatment. Upper diagonal: HR and 95% CrI from direct pairwise meta-analysis. HR <1 favour the row defining treatment, HR >1 favour the column defining treatment. Cells in bold type indicate effects that do not cross the line of no treatment effect.

*indicates that the surgical procedure was included in the cost-effectiveness analysis

Table 2. Cost-effectiveness of surgical procedures for adult women with anterior POP; results of probabilistic analysis

Surgical procedure	Mean QALYs*	Mean total costs (£)	Incremental analysis and ICERs (£/QALY)	Mean NMB (£)	Ranking by highest NMB	Probability of being cost-effective at a £20,000–£30,000/QALY threshold
AC only	9.667	£4,192	Dominant	£189,156	1	0.695-0.676
AC with biological mesh	9.641	£4,959	Dominated	£187,869	2	0.177-0.211
AC with synthetic partially absorbable mesh	9.557	£4,809	Dominated	£186,337	3	0.098-0.091
AC with synthetic non-absorbable mesh	9.558	£4,859	Dominated	£186,306	4	0.030-0.022

Mean values for a cohort of 100 women over 15 years.

ICER, incremental cost-effectiveness ratio; NMB, net monetary benefit, estimated using a willingness to pay £20,000/QALY.

*Procedures ranked from the most to the least effective according to the number of QALYs.

effects associated with mesh procedures, it was conservatively modelled that treatment effectiveness at 4 years onwards for mesh procedures will be the same as for non-mesh procedures. This is in keeping with the review of observational studies, which suggests that the long-term recurrence rates following mesh surgery and non-mesh surgery were nearly identical.⁹

Complication rates were poorly reported; therefore, safety assessment was limited to data from single studies and at best provides only proxies for serious mesh complications. Despite this limitation, the conclusions were robust to changes in complication rates.

It was recognised that POP procedures may be associated with a number of other complications. For example, de novo stress urinary incontinence has been recognised as an important complication. However, the rate of stress urinary incontinence is similar following mesh and non-mesh surgery.⁹ The risk of urge incontinence is higher following mesh surgery.⁹ However, the majority of of urge incontinence cases are successfully managed with low-cost anticholinergic drugs and only a small proportion of women require treatment with higher-cost botulinum toxin. Similarly, in most cases constipation is easily managed with low-cost laxatives. Women who have obstructed defecation may require more intensive management, but the rate of constipation is higher following mesh surgery and the exclusion of constipation only underestimated the cost-effectiveness of non-mesh surgery.⁹ The management of dyspareunia is partially captured by considering pain complications and as the rate of dyspareunia is higher in the mesh surgery, its omission only underestimated the cost-effectiveness of non-mesh surgery.⁹

Another limitation of the study is that the literature search is over a year old. However, a literature search on PubMed (conducted April 2019) failed to identify any relevant new RCTs. Also, the NICE GC were not aware of any relevant recently published RCTs.

Interpretation

Our finding that AC augmented with mesh is cost-ineffective is in line with current thinking among healthcare professionals. Even though the effectiveness data favour mesh, it is associated with an increased risk of complications. The cost-effectiveness analysis confirmed that mesh complications have a longer-term impact on women, and also on healthcare resources. It is worth pointing out that the clinical effectiveness plays a lesser role in the cost-effectiveness estimate because the probability of surgically managed recurrence is low and a large proportion of women are asymptomatic following recurrence.

Our findings are consistent with a previous UK analysis, which also found mesh augmentation to be cost-ineffective.³⁵ The findings of a second economic evaluation were inconclusive; however, the results are not directly comparable because they included women with AC and/or posterior colporrhaphy.²²

Conclusions

Overall, the analysis indicated that mesh was cost-ineffective in the primary repair of anterior POP, and, despite little long-term evidence on the efficacy and complications, our findings were robust. As a result, the NICE guideline recommended that mesh be considered only in recurrent anterior POP if apical support is adequate or an abdominal approach is contraindicated, after regional multidisciplinary team review and a detailed discussion with the woman about the risks of mesh insertion.

Given the safety concerns associated with mesh products, future research may be unethical to answer this question with more certainty. However, as recommended in the NICE guideline, a national data registry would provide a better picture of long-term mesh complications, enable a more definite assessment of the cost-effectiveness of mesh procedures, and help to identify clinically important

subgroups where a mesh procedure may be an option. In the meantime, the data from this analysis should preclude the use of mesh products in women who require primary anterior POP repair.

Disclosure of interest

CD and SD received support from the NICE Guidelines Technical Support Unit, University of Bristol, with funding from the Centre for Guidelines (NICE). The views expressed do not represent those of NICE. EH, ES, IM and PC received support from the National Guideline Alliance, which was in receipt of funding from NICE for the submitted work. FM received personal fees from NICE during the conduct of the study. KW was the topic lead for Urinary Incontinence on the NICE Guideline Committee for Incontinence and Pelvic Organ Prolapse. MC declares no conflict of interest. RK was the topic lead for Pelvic Organ Prolapse on the NICE Guideline Committee for Incontinence and Pelvic Organ Prolapse. Completed disclosure of interest forms are available to view online as supporting information.

Contribution of authorship

CD contributed to the NMA and conducted inconsistency checks. EH performed and CM assisted with the search strategy. ES carried out the initial NMA and the economic analysis. IM contributed to the NMA planning. SD contributed to the NMA planning and inconsistency checks. KW, RK and FM provided clinical input and interpretation of the results and their clinical implications. MH and CM provided clinical input. PC carried out the systematic reviews and analyses. VDN oversaw the development of the systematic reviews and analyses. All authors contributed to the write up of the manuscript and approved the final version for submission.

Funding

The guideline referred to in this article was produced by the National Guideline Alliance (NGA) at the Royal College of Obstetricians and Gynaecologists (RCOG) for NICE. The views expressed in this article are those of the authors and not necessarily those of RCOG, NGA or NICE. 'National Institute for Health and Care Excellence (2019) Urinary incontinence and pelvic organ prolapse in women: management. Available from <https://www.nice.org.uk/guidance/ng123>'. EH, ES, IM, PC and VDN received support from the NGA, which was in receipt of funding from NICE for the submitted work. SD and CD received support from the NICE Guidelines Technical Support Unit, University of Bristol, with funding from the Centre for Guidelines (NICE).

Acknowledgements

We thank the Guideline Committee for the NICE guideline on 'Urinary incontinence and pelvic organ prolapse in

women: management' (Fergus Macbeth, Karen Ward, Rohna Kearney, Carmel Ramage, Catherine Heffernan, Doreen McClurg, Jacqueline Emkes, Julian Spinks, Kate Welford, Lucy Ryan, Polly Harris, Suzanne Biers, Vikky Morris). We also thank co-opted Guideline Committee members including Carol Paton, James Stephenson, Sarah Love Jones and Steven Brown; and also Charlotte Mahoney (Clinical Fellow), Melanie Davies (NGA Clinical Advisor) and Steve Pilling (NGA Clinical Advisor).

Supporting Information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Table S1. Input parameters used in the economic model for adult women with anterior POP.

Table S2. Characteristics of the included studies in the NMA and references.

Table S3. Final data file for the NMA.

Table S4. Summary of deterministic sensitivity analyses.

Appendix S1. Search strategy.

Appendix S2. NMA model fit, selection and inconsistency checks.

Appendix S3. Description of Markov model for comparison of different surgical procedures for women with anterior POP. ■

References

- Zacche MM, Mukhopadhyay S, Giarenis I. Trends in prolapse surgery in England. *Int Urogynecol J* 2018;29:1689–1695.
- Haylen BT, Maher CF, Barber MD, Camargo S, Dandolu V, Digesu A, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic organ prolapse (POP). *Int Urogynecol J* 2016;27:655–84.
- Monti M, Schiavi MC, Colagiovanni V, Sciuga V, D'Oria O, Cerone G, et al. Effectiveness, quality of life and sexual functions in women with anterior compartment prolapse treated by native tissue repair: a mini-review. *Minerva Ginecol* 2018;71:18–24.
- Halpern-Elenskaia K, Umek W, Bodner-Adler B, Hanzal E. Anterior colporrhaphy: a standard operation? Systematic review of the technical aspects of a common procedure in randomized controlled trials. *Int Urogynecol J* 2018;29:781–8.
- England. N. Mesh Oversight Group Report.; 2017.
- Government S. Scottish Independent Review of the use, safety and efficacy of transvaginal mesh implants in the treatment of stress urinary incontinence and pelvic organ prolapse in women. 2017.
- FDA. *FDA Strengthens Requirements for Surgical Mesh for the Transvaginal Repair of Pelvic Organ Prolapse to Address Safety Risks*. Silver Spring, MD: FDA; 2016.
- SCENIHR. *Opinion on the safety of surgical meshes used in urogynecological surgery*. Luxembourg: SCENIHR; 2015.
- NICE. *Urinary Incontinence (update) and Pelvic Organ Prolapse in Women: Management, Clinical Guideline 123*. London: National Institute for Health and Care Excellence; 2019.

- 10 Higgins J, Green S. editors. *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011.
- 11 Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. *BMJ* 2005;331(7521):897–900.
- 12 Dias S, Sutton AJ, Ades AE, Welton NJ. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. *Med Decis Making* 2013;33:607–17.
- 13 Glenny AM, Altman DG, Song F, Sakarovich C, Deeks JJ, D'Amico R, et al. Indirect comparisons of competing interventions. *Health Technol Assess* 2005;9:1–134, iii–iv.
- 14 Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. *Res Synth Methods* 2012;3:80–97.
- 15 Dea L. *The BUGS Book*. Boca Raton, FL: CRC Press; 2013.
- 16 Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE. Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials. *Med Decis Making* 2013;33:641–56.
- 17 van Valkenhoef G, Dias S, Ades AE, Welton NJ. Automated generation of node-splitting models for assessment of inconsistency in network meta-analysis. *Res Synth Methods* 2016;7:80–93.
- 18 Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. *Stat Med* 2010;29:932–44.
- 19 Lowenstein E, Moller LA, Laigaard J, Gimbel H. Reoperation for pelvic organ prolapse: a Danish cohort study with 15–20 years' follow-up. *Int Urogynecol J* 2018;29:119–24.
- 20 Rudnicki M, Laurikainen E, Pogosean R, Kinne I, Jakobsson U, Teleman P. A 3-year follow-up after anterior colporrhaphy compared with collagen-coated transvaginal mesh for anterior vaginal wall prolapse: a randomised controlled trial. *BJOG* 2016;123:136–42.
- 21 Denman MA, Gregory WT, Boyles SH, Smith V, Edwards SR, Clark AL. Reoperation 10 years after surgically managed pelvic organ prolapse and urinary incontinence. *Am J Obstet Gynecol* 2008;198:555 e1–5.
- 22 Glazener C, Breeman S, Elders A, Hemming C, Cooper K, Freeman R, et al. Clinical effectiveness and cost-effectiveness of surgical options for the management of anterior and/or posterior vaginal wall prolapse: two randomised controlled trials within a comprehensive cohort study – results from the PROSPECT Study. *Health Technol Assess* 2016;20(95):1–452.
- 23 RCOG. *Consent Advice No. 5. Vaginal Surgery for Prolapse*. London: RCOG; 2009.
- 24 Jacquetin B, Hinoul P, Gauld J, Fatton B, Rosenthal C, Clave H, et al. Total transvaginal mesh (TVM) technique for treatment of pelvic organ prolapse: a 5-year prospective follow-up study. *Int Urogynecol J* 2013;24:1679–86.
- 25 Laso-Garcia IM, Rodriguez-Cabello MA, Jimenez-Cidre MA, Orosa-Andrada A, Carracedo-Calvo D, Lopez-Fando L, et al. Prospective long-term results, complications and risk factors in pelvic organ prolapse treatment with vaginal mesh. *Eur J Obstet Gynecol Reprod Biol* 2017;211:62–7.
- 26 Glazener C, Breeman S, Elders A, Hemming C, Cooper K, Freeman R, et al. Clinical effectiveness and cost-effectiveness of surgical options for the management of anterior and/or posterior vaginal wall prolapse: two randomised controlled trials within a comprehensive cohort study - results from the PROSPECT Study. *Health Technol Assess* 2016;20:1–452.
- 27 Miedel A, Tegerstedt G, Morlin B, Hammarstrom M. A 5-year prospective follow-up study of vaginal surgery for pelvic organ prolapse. *Int Urogynecol J Pelvic Floor Dysfunct* 2008;19:1593–601.
- 28 DHSC. *NHS Reference Costs 2016/17*. London: Department of Health and Social Care; 2018.
- 29 BNF. *Joint Formulary Committee*. London: British National Formulary (online); 2018.
- 30 Curtis LA, Burns A. *Unit Costs of Health and Social Care 2017*. Canterbury: University of Kent: Personal Social Services Research Unit; 2017.
- 31 NHSBSA. *NHS Electronic Drug Tariff*. Newcastle upon Tyne: Compiled on behalf of the Department of Health by the NHS Business Services Authority, NHS Prescription Services; 2018.
- 32 Briggs A, Schulpher M, Claxton K. *Decision Modelling for Health Economic Evaluation*. New York: Oxford University Press; 2006.
- 33 Lamblin G, Van-Nieuwenhuysse A, Chabert P, Lebaill-Carval K, Moret S, Mellier G. A randomized controlled trial comparing anatomical and functional outcome between vaginal colposuspension and transvaginal mesh. *Int Urogynecol J* 2014;25:961–70.
- 34 Altman D, Vayrynen T, Engh ME, Axelsen S, Falconer C, Nordic Transvaginal Mesh G. Anterior colporrhaphy versus transvaginal mesh for pelvic-organ prolapse. *N Engl J Med* 2011;364:1826–36.
- 35 Jacklin P, Duckett J. A decision-analytic Markov model to compare the cost-utility of anterior repair augmented with synthetic mesh compared with non-mesh repair in women with surgically treated prolapse. *BJOG* 2013;120:217–23.